Zeegap Dosage

Zeegap Dosage in Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

The maximum recommended dose of Zeegap is 100mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Dosing should start at 50 mg 3 times a day (150 mg/day) and may be gradually increased to 300 mg/day within 1 week based on efficacy and tolerability. Since pregabalin is eliminated primarily by renal excretion, the dose should be adjusted for patients with reduced renal function.

Postherpetic Neuralgia

Dose of pregabalin is 75 to 150 mg two times a day, or 50 to 100 mg 3 times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Dose should be started at 75 mg 2 times a day, or 50 mg 3 times a day (150 mg/day) and may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Patients who does not have sufficient pain relieve following 2 to 4 weeks of treatment with 300 mg/day, and who are able to tolerate pregabalin, may be treated with up to 300 mg two times a day, or 200 mg three times a day (600 mg/day).

Adjunctive Therapy for Adult Patients with Partial onset Seizures

Dose of pregabalin 150 to 600 mg/day has been shown to be effective as adjunctive therapy in the treatment of partial onset seizures in adults. The total daily does should be divided into two or three times daily. Since pregabalin is eliminated primarily by renal system, the dose should be adjusted for patients with reduced renal function.

Management of Fibromyalgia

Recommended dose of pregabalin for the treatment of fibromyalgia is 300 to 450 mg/day. Dosing should start at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability.

Patients with Renal Impairment

With reference to dose-dependent adverse reactions and as pregabalin is eliminated primarily by renal excretion, the dose should be adjusted in patients with reduced renal function. Dosage adjustment in patients with renal impairment should be based on creatinine clearance (CLcr).

Use in Pregnancy

Patients should be instructed to notify their physician, if they become pregnant or intend to become pregnant during therapy, and to notify their physician if they are breast feeding or intend to breast feed during therapy.

Drug Interactions

As pregabalin is excreted unchanged in the urine, undergoes negligible metabolism in humans (< 2% of a dose recovered in urine as metabolites), and does not binds with plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement. In vitro and in vivo studies showed that pregabalin is unlikely to be involved in significant pharmacokinetic drug interactions. Specifically, there are no pharmacokinetic interactions between pregabalin and the following antiepileptic drugs: carbamazepine, valproic acid, lamotrigine, phenytoin, phenobarbital, and topiramate. Important pharmacokinetic interactions would also not be expected to occur between pregabalin and commonly used antiepileptic drugs.

Related Links

Free Prescription Drugs Information by Dr.Thomas Williams